Biomerica (BMRA) Competitors $2.96 +0.05 (+1.72%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.91 -0.05 (-1.69%) As of 10/24/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRA vs. ANVS, XCUR, AKTX, KZR, RNTX, IMA, SONN, CVKD, LNAI, and DAREShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Annovis Bio (ANVS), Exicure (XCUR), Akari Therapeutics (AKTX), Kezar Life Sciences (KZR), Rein Therapeutics (RNTX), ImageneBio (IMA), Sonnet BioTherapeutics (SONN), Cadrenal Therapeutics (CVKD), Lunai Bioworks (LNAI), and Dare Bioscience (DARE). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Its Competitors Annovis Bio Exicure Akari Therapeutics Kezar Life Sciences Rein Therapeutics ImageneBio Sonnet BioTherapeutics Cadrenal Therapeutics Lunai Bioworks Dare Bioscience Annovis Bio (NYSE:ANVS) and Biomerica (NASDAQ:BMRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership. Do analysts rate ANVS or BMRA? Annovis Bio currently has a consensus target price of $13.50, suggesting a potential upside of 560.15%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20Biomerica 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has more volatility & risk, ANVS or BMRA? Annovis Bio has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, Biomerica has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. Which has preferable earnings & valuation, ANVS or BMRA? Biomerica has higher revenue and earnings than Annovis Bio. Biomerica is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$24.59M-$2.04-1.00Biomerica$4.88M1.79-$4.97M-$0.96-3.08 Is ANVS or BMRA more profitable? Annovis Bio has a net margin of 0.00% compared to Biomerica's net margin of -74.84%. Biomerica's return on equity of -73.44% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A -206.01% -158.26% Biomerica -74.84%-73.44%-53.26% Does the media refer more to ANVS or BMRA? In the previous week, Biomerica had 1 more articles in the media than Annovis Bio. MarketBeat recorded 2 mentions for Biomerica and 1 mentions for Annovis Bio. Biomerica's average media sentiment score of 0.95 beat Annovis Bio's score of 0.00 indicating that Biomerica is being referred to more favorably in the news media. Company Overall Sentiment Annovis Bio Neutral Biomerica Positive Do insiders & institutionals have more ownership in ANVS or BMRA? 15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 22.3% of Biomerica shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 15.0% of Biomerica shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryBiomerica beats Annovis Bio on 8 of the 15 factors compared between the two stocks. Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.58M$2.97B$6.24B$10.65BDividend YieldN/A57.75%5.71%4.82%P/E Ratio-3.0826.3230.6130.44Price / Sales1.79782.63596.73191.77Price / CashN/A168.3237.0161.44Price / Book1.695.6512.036.60Net Income-$4.97M$33.06M$3.32B$276.82M7 Day Performance-0.67%3.16%1.89%2.55%1 Month Performance5.71%8.14%7.71%3.76%1 Year Performance25.42%-2.49%56.33%33.04% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomerica0.8113 of 5 stars$2.96+1.7%N/A+24.3%$8.58M$4.88M-3.0860Short Interest ↓ANVSAnnovis Bio2.5659 of 5 stars$1.68+1.2%$17.33+931.7%-77.5%$32.74MN/A-0.823Analyst ForecastGap DownXCURExicure1.7476 of 5 stars$5.10-0.8%N/A+114.6%$32.22MN/A-1.3150Gap UpAKTXAkari Therapeutics2.8723 of 5 stars$0.98+4.0%$3.30+236.7%-67.4%$31.97MN/A0.009Analyst ForecastShort Interest ↑KZRKezar Life Sciences3.0013 of 5 stars$4.33+0.9%$9.00+107.9%-23.2%$31.70M$7M-0.4560Gap DownHigh Trading VolumeRNTXRein Therapeutics3.2156 of 5 stars$1.34+1.5%$10.00+646.3%N/A$31.23MN/A-0.509Gap UpIMAImageneBio3.661 of 5 stars$7.64-0.7%$35.50+364.7%-61.0%$30.64M$9.16M-0.9970News CoverageAnalyst ForecastGap UpSONNSonnet BioTherapeutics2.2574 of 5 stars$4.31-1.4%$20.00+364.0%-21.6%$29.44M$20K0.0010News CoverageCVKDCadrenal Therapeutics3.2644 of 5 stars$14.10+0.8%$32.00+127.0%-15.7%$28.91MN/A-1.594Analyst ForecastLNAILunai BioworksN/A$1.22+5.2%N/AN/A$28.28MN/A-0.1620DAREDare Bioscience2.3515 of 5 stars$2.06-2.8%$10.00+385.4%-39.7%$27.77M$10K-0.9630Analyst Forecast Related Companies and Tools Related Companies Annovis Bio Alternatives Exicure Alternatives Akari Therapeutics Alternatives Kezar Life Sciences Alternatives Rein Therapeutics Alternatives ImageneBio Alternatives Sonnet BioTherapeutics Alternatives Cadrenal Therapeutics Alternatives Lunai Bioworks Alternatives Dare Bioscience Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRA) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
